Countdown to
`the 10th Anniversary Scrip Awards
`
`The countdown to the 10th annual Scrip Awards, to be held on 3 December at London’s Lancaster Hotel, has now begun
`in earnest following the recent shortlist announcement. In the last remaining week until the awards ceremony, we will be
`showcasing the finalists from each of the categories.
`Management Team of the Year
`Scrip’s Management Team of the Year Award will honor the achievements of management teams whether they are from the top tier of
`management at a pharma or biotech company or a team responsible for specific operations or projects within a company. The shortlist is:
`
`AbbVie’s executive leadership team
`Under this seven-strong team, AbbVie has enjoyed a
`successful inaugural year as an independent company following
`its separation from Abbott, meeting or exceeding all its goals.
`Sales in 2013 totaled $18.8bn, driven by its substantial growth
`of existing products including top-seller Humira, which
`enabled the company to deliver a total shareholder return
`of 60%. Significant resources were devoted to advancing
`expanding the pipeline which now has 10 products at Phase III
`or registration including for hepatitis C.
`
`Horizon Discovery’s management team
`This six-strong team has overseen a vintage year for
`Horizon Discovery Group. It completed a successful
`IPO in less than 11 weeks from initiation to listing on
`AIM with a market capitalization of £120.5m, in March,
`and raised £68.6m placed at the top of its pricing range
`in a significantly oversubscribed offering, well above the
`original target of £25m. Horizon also acquired US firm
`CombinatoRx establishing its US headquarters in the heart
`of its East Coast customer base.
`
`Prosensa’s management team
`Prosensa’s management showed its quality by successfully
`navigating a year of triumph and disaster. In just six weeks
`the team drove through a trailblazing listing on NASDAQ,
`the first IPO of a European biotech company in 10 years,
`and then faced the set-back of unexpectedly negative
`results for its Phase III trial of drisapersen. Having regained
`the rights to the product from partner GlaxoSmithKline it
`has now forged a regulatory path forward with the FDA.
`
`AstraZeneca’s business development
`operations team
`Against a background of challenge and change, AstraZeneca’s
`business development operations team executed multiple
`strategically important and high-quality transactions in the
`qualifying period. The ten-strong team oversaw six major
`deals that strengthened the company’s priority therapeutic
`areas, including CV/metabolism, respiratory, inflammation,
`autoimmune and oncology: the acquisitions of Pearl
`Therapeutics, Omthera Pharmaceuticals, Amplimmune and
`Bristol-Myers Squibb’s interest in their diabetes alliance, plus
`licensing deals with Merck and Synairgen.
`
`PPD’s site intelligence and activation
`management team
`This team was created in 2013 to have a singular focus on
`effective clinical trial start ups and provide a competitive
`advantage to PPD in this area. Its greatest success to date
`was the completion of a major change in management
`effort without significant loss of employees or their
`engagement, and achieving customer-facing operational
`objectives. During the qualifying year, PPD observed a
`nearly 30% reduction in site activation cycle times.
`
`Merck KGaA / Merck Serono’s regional
`clinical operations team
`This team is an example to others in making bold yet
`necessary decisions in the face of difficulties. With
`setbacks for new drug candidates, impending pipeline
`decline and flat growth, Merck decided on a major
`restructuring and to pursue an R&D turnaround. The team
`arrived at an innovative model not yet tried by industry
`peers to drive functional excellence, ensure compliance,
`improve capabilities and improve efficiency, and is an
`example of embracing risk, and challenging the status quo.
`
`Best New Drug
`Scrip’s Best New Drug Award recognises excellence in pharmaceutical development. Launching innovative new products is the most important
`function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D. The shortlist is:
`
`Roche’s Gazyva/Gazyvaro (obinutuzumab)
`Roche’s Gazyva is the first and only type II
`glycoengineered anti-CD20 monoclonal antibody and was
`the first drug with Breakthrough Therapy Designation to
`be approved by the FDA, when it was licensed for use
`in the treatment of chronic lymphocytic leukemia and
`launched in November 2013. In its Phase III head-to-head
`CLL11 study, Gazyva showed superiority over standard
`treatment MabThera, allowing patients to live a year
`longer without their disease worsening.
`
`Genzyme’s Lemtrada (alemtuzumab)
`Lemtrada, an anti-CD52 humanized monoclonal
`antibody that acts to reset the immune system, is the first
`monotherapy for multiple sclerosis to show improved
`efficacy on relapse rates and disability accumulation against
`an active comparator, high dose beta interferon 1a. With
`its efficacy profile, yearly administration schedule that
`improves compliance, and durable treatment effect,
`Lemtrada has the potential to change the way multiple
`sclerosis is treated.
`
`Roche’s Kadcyla (trastuzumab emtansine)
`Kadcyla is an innovative targeted breast cancer drug that
`represents a new way of treating advanced HER2-positive
`breast cancer. The first-of-its-kind antibody-drug conjugate
`consists of a HER2-targeted antibody (the active ingredient
`of Herceptin) linked with a chemotherapy, DM1, to give a
`double blockade attack on the cancer cells, by seeking out
`the cancer cells and stopping their growth signals, and by
`releasing a toxic payload to destroy them from within.
`
`Gilead’s Sovaldi (sofosbuvir)
`The first approval of Sovaldi, an oral nucleotide analog
`inhibitor of the HCV NS5B polymerase enzyme, in the US
`in late 2013 marked the beginning of a new era in hepatitis
`C treatment. In clinical studies, Sovaldi in combination
`with other agents achieved very high cure rates while
`shortening the duration of treatment to as little as 12
`weeks and reducing or completely eliminating the need for
`interferon injections, depending on the viral genotype.
`
`To reserve your table for the awards ceremony, contact:
`
`Carl Richardson
`Global Sponsorship Manager
`Email: carl.richardson@informa.com
`Tel: +44 (0)207 017 5025
`
`Sponsored by:
`
`Iroko Pharmaceuticals’ Zorvolex
`(diclofenac) capsules
`By altering the absorption properties of diclofenac through
`Iroko’s proprietary SoluMatrix fine particle technology,
`Zorvolex was developed to align with the FDA and other
`professional organizations that recommend that NSAIDs
`be used at the lowest effective dose for the shortest
`duration due to safety concerns. The product meets a
`need for an NSAID option that can provide acute pain
`relief with lower overall systemic exposure to the drug.
`
`scripawards.com
`
`Page 1
`
`LUPIN EX. 1032
`Lupin v. iCeutica
`US Patent No. 9,017,721
`
`